Loading stock data…
NewAmsterdam Pharma Company N.V (NAMS)
$33.87+0.63 (+1.90%)
Market ClosedLast close Jun 29
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
NewAmsterdam Pharma Company N.V. in the Healthcare sector is trading at $33.87 with a market capitalization of $4.0B. Wall Street consensus targets $49.19 (14 analysts), implying a +45.2% move over the next 12 months. The stock is currently 20% below its 52-week high of $42.20, remaining 1.2% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +45.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.04M↑ | $32,000↓ | $348,000↓ | $19.14M↑ | $2.98M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$58.42M↑ | -$65.98M↓ | -$55.14M↓ | -$35.63M↑ | -$68.92M |
| Net Income | -$48.44M↑ | -$74.92M↓ | -$72.00M↓ | -$17.36M↑ | -$39.53M |
Peer Comparison
JNJUNHPFE
Fundamentals
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP)...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.96B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.08
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-31.98%
Volume
Today's trading volume
1.15M
Recent News
A Look At NewAmsterdam Pharma (NAMS) Valuation After Recent Share Price Weakness
Recent trading context for NewAmsterdam Pharma (NasdaqGM:NAMS) NewAmsterdam Pharma (NasdaqGM:NAMS) has drawn fresh attention after recent trading, with the stock closing at US$29.33. The move comes alongside a month-long decline of about 26% and a year-to-date drop near 17%. See our latest analysis for NewAmsterdam Pharma. The recent 1 month share price return, down 25.92%, suggests momentum has cooled in the short term, even as the 1 year total shareholder return of 43.07% and very large 3...
Billionaire Stanley Druckenmiller Likes This Small-Cap Pharma Stock in 2026
We just covered the 10 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller. NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) ranks #5 (see 5 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller). Druckenmiller’s Stake: $98,275,000 Druckenmiller likes asymmetric bets where he can risk a small position for potentially large upside. NAMS falls in […]
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge
This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors.
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean
Dyne Therapeutics targets rare muscle diseases with its FORCE platform, aiming to meet unmet needs in neuromuscular therapeutics.
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
A week ago, NewAmsterdam Pharma Company N.V. ( NASDAQ:NAMS ) came out with a strong set of quarterly numbers that could...